David E. Gilham
Manchester, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
In Remembrance of Professor Zelig Eshhar: A Life Committed to CAR-T.
Journal: Human gene therapy
Published: June 18, 2026
In Remembrance of Professor Zelig Eshhar: A Life Committed to CAR-T.
Journal: Human gene therapy
Published: March 28, 2026
Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies.
Journal: EJHaem
Published: April 18, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Journal: The Lancet. Haematology
Published: September 28, 2022
Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: March 24, 2021
CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth.
Journal: JCI insight
Published: April 03, 2020
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: August 01, 2019
The integrated stress response promotes B7H6 expression.
Journal: Journal of molecular medicine (Berlin, Germany)
Published: June 03, 2019
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
Journal: Journal of visualized experiments : JoVE
Published: November 06, 2018
Overcoming Target Driven Fratricide for T Cell Therapy.
Journal: Frontiers in immunology
Published: August 08, 2018
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Journal: Cancer immunology research
Published: May 25, 2018
Last Updated: 09/26/2026